Cronos Group partners with Ginkgo Bioworks to develop cultured cannabinoids valued up to $122M
Cronos Group partners with Ginkgo Bioworks to develop cultured cannabinoids valued up to $122M The passage details a commercial biotech partnership between a Canadian cannabis firm and a synthetic biology startup. It provides financial terms and milestones but does not implicate high‑ranking political figures, intelligence agencies, or controversial misconduct. The lead is primarily a business development note with limited investigative value. Key insights: Agreement announced September 2018 between Cronos Group and Ginkgo Bioworks.; Total deal value up to $122 million, including $22 million R&D funding and up to $100 million in Cronos common shares.; Ginkgo to engineer yeast strains to produce eight specific cannabinoids at cost <$1,000/kg.
Summary
Cronos Group partners with Ginkgo Bioworks to develop cultured cannabinoids valued up to $122M The passage details a commercial biotech partnership between a Canadian cannabis firm and a synthetic biology startup. It provides financial terms and milestones but does not implicate high‑ranking political figures, intelligence agencies, or controversial misconduct. The lead is primarily a business development note with limited investigative value. Key insights: Agreement announced September 2018 between Cronos Group and Ginkgo Bioworks.; Total deal value up to $122 million, including $22 million R&D funding and up to $100 million in Cronos common shares.; Ginkgo to engineer yeast strains to produce eight specific cannabinoids at cost <$1,000/kg.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.